How metabolism controls aggressive lung cancer cells
Metabolic control of malignant fates in lung cancer
Researchers are changing cancer cell metabolism to try to make lung adenocarcinoma cells less aggressive and easier to treat for people with lung adenocarcinoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11238515 on NIH RePORTER |
What this research studies
This work uses lab-grown tumor cells from people and mice to change how cancer cells use a key energy pathway called the TCA cycle. By shifting the pathway into different configurations, researchers aim to push cancer cells into more normal, less aggressive states or into the opposite state to see what supports spread and treatment resistance. Experiments will include human-derived cell lines and mouse models and will manipulate specific metabolic enzymes to track effects on cell behavior. The focus is on understanding metabolic drivers of malignant states rather than testing a drug in patients right now.
Who could benefit from this research
Good fit: Adults diagnosed with lung adenocarcinoma, especially those able to provide tumor samples from surgery or biopsy for research, would be most relevant to this work.
Not a fit: People with other types of lung cancer or those seeking immediate treatment changes should not expect direct personal benefit from these lab-focused experiments.
Why it matters
Potential benefit: If successful, this research could point to metabolic targets that lead to new treatments reducing relapse and resistance in lung adenocarcinoma.
How similar studies have performed: Prior laboratory studies show that changing cancer metabolism can alter tumor behavior, but targeting non-canonical TCA configurations in lung adenocarcinoma is a newer approach with limited clinical testing so far.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Finley, Lydia — Sloan-Kettering Inst Can Research
- Study coordinator: Finley, Lydia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.